<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853306</url>
  </required_header>
  <id_info>
    <org_study_id>M13-695</org_study_id>
    <nct_id>NCT01853306</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 part phase 1 study to evaluate the safety, pharmacokinetic and oral&#xD;
      bioavailability of veliparib in subjects with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 18, 2013</start_date>
  <completion_date type="Actual">June 29, 2017</completion_date>
  <primary_completion_date type="Actual">May 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 2 - Dose Escalation Cohort: Pharmacokinetic testing</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Cmax, Tmax ,and AUC, and safety parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Pharmacokinetic profile</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>The following pharmacokinetic parameters will be analyzed: Tmax, the terminal phase elimination rate constant (β), the natural logarithms of Cmax, AUCt and AUC∞.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Safety Expanded Cohort: Number of subjects with adverse events</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Safety Expanded Cohort: Vital signs</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood pressure, Heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Safety Expanded Cohort: Laboratory tests</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Hematology, Chemistry, Urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events who receive the extended release formulations of veliparib.</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Oncology</condition>
  <condition>BRCA Mutated</condition>
  <condition>High Grade Serous Ovarian Cancer</condition>
  <condition>BRCA Mutated Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Veliparib formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>veliparib formulation A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veliparib formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib formulation B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veliparib formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>veliparib formulation C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>veliparib</description>
    <arm_group_label>Veliparib formulation A</arm_group_label>
    <arm_group_label>Veliparib formulation B</arm_group_label>
    <arm_group_label>Veliparib formulation C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Part 1 and 2: Histologically or cytologically confirmed malignancy that is metastatic&#xD;
             or unresectable and for which standard curative measures or other therapy that may&#xD;
             provide clinical benefit do not exist or are no longer effective. Subjects must also&#xD;
             1) have a documented BRCA1 or BRCA2 mutation that is considered to be deleterious by&#xD;
             the investigator, OR 2) have high grade serous ovarian, fallopian tube, or peritoneal&#xD;
             cancer. Subjects with molecular features indicative of DNA repair defects (such as&#xD;
             mutation in the Fanconi anemia pathway genes or methylation of the BRCA1 promoter) may&#xD;
             be considered eligible for following discussion with the medical monitor. Part 3:&#xD;
             Histologically or cytologically confirmed breast, ovarian, fallopian tube or primary&#xD;
             peritoneal cancer that is metastatic or unresectable and for which standard curative&#xD;
             measures or other therapy that may provide clinical benefit do not exist or are no&#xD;
             longer effective. Platinum-resistant ovarian cancer is not permitted. Subjects must&#xD;
             also 1) have a documented BRCA1 or BRCA2 mutation that is considered to be deleterious&#xD;
             by the investigator and 2) have received 3 or fewer regimens of cytotoxic chemotherapy&#xD;
             in the metastatic setting and 3) have evaluable disease as defined by RECIST 1.1 or&#xD;
             GCIC-CA-125 criteria.&#xD;
&#xD;
          2. Subject must be at least 18 years of age.&#xD;
&#xD;
          3. Completion of last anti-cancer therapy must be at least 28 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.&#xD;
&#xD;
          5. Subject must have adequate hematologic, renal and hepatic function as follows:&#xD;
&#xD;
               -  Bone Marrow: Absolute neutrophil count ANC ≥ 1,500/mm3 (1.5 × 109/L); Platelets ≥&#xD;
                  100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.5 g/dL (1.4 mmol/L). Subjects with&#xD;
                  hemoglobin ≥ 9.5 g/dL (1.4 mmol/L) following transfusion are eligible;&#xD;
&#xD;
               -  Renal function: A calculated creatinine clearance value of ≥ 50 mL/min as&#xD;
                  determined by the Cockcroft Gault formula or a creatinine clearance value of ≥ 50&#xD;
                  mL/min based on a 24-hour urine collection;&#xD;
&#xD;
               -  Hepatic function: AST and ALT ≤ 2.5 × the upper normal limit of institution's&#xD;
                  normal range. For subjects with liver metastases, AST and ALT ≤ 5 × the upper&#xD;
                  normal limit of institution's normal range;&#xD;
&#xD;
               -  Bilirubin: → 1.5 × the upper normal limit of institution's normal range.&#xD;
&#xD;
          6. Women of childbearing potential and men must agree to use adequate contraception prior&#xD;
             to the study entry, for the duration of study participation and up to 3 months&#xD;
             following completion of therapy. Women of childbearing potential must have a negative&#xD;
             pregnancy test within 7 days prior to initiation of treatment and/or post menopausal&#xD;
             women must be amenorrheic for at least 12 months to be considered of non-childbearing&#xD;
             potential.&#xD;
&#xD;
               -  total abstinence from sexual intercourse as the preferred life style of the&#xD;
                  subject; periodic abstinence is not acceptable;&#xD;
&#xD;
               -  vasectomized partner(s);&#xD;
&#xD;
               -  hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months&#xD;
                  prior to study drug administration;&#xD;
&#xD;
               -  intrauterine device (IUD);&#xD;
&#xD;
               -  Male subjects (including those who are vasectomized) whose partners are pregnant&#xD;
                  or might be pregnant must agree to use condoms for the duration of the study and&#xD;
                  for 90 days following completion if therapy.&#xD;
&#xD;
          7. Subject must be capable of understanding and complying with parameters as outlined in&#xD;
             the protocol and able to sign informed consent, approved by an Institutional Review&#xD;
             Board (IRB) prior to the initiation of any screening or study specific procedures.&#xD;
&#xD;
          8. Must voluntarily sign and date each informed consent, approved by an Independent&#xD;
             Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of&#xD;
             any screening or study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject must not have received anti-tumor radiotherapy, biologic therapy,&#xD;
             chemotherapy, or immunotherapy within 28 days or 5 half lives (whichever is shorter)&#xD;
             of the start of Day 1. The subject must not have received hormonal therapy for&#xD;
             anti-tumor purposes within 1 week prior to the start of Cycle 1 Day 1.&#xD;
&#xD;
          2. Subject must not have known untreated brain or meningeal metastases. CT scans are not&#xD;
             required to rule out brain or meningeal metastases unless there is a clinical&#xD;
             suspicion of central nervous system disease. Subjects with treated brain metastases&#xD;
             that are radiographically or clinically stable for at least 4 weeks after therapy and&#xD;
             have no evidence of cavitation or hemorrhage in the brain lesion(s) are eligible,&#xD;
             provided that they are asymptomatic and do not require corticosteroids (must have&#xD;
             discontinued steroids at least one week prior to study drug administration).&#xD;
&#xD;
          3. Clinically significant and uncontrolled major medical condition(s) including but not&#xD;
             limited to:&#xD;
&#xD;
               -  Uncontrolled nausea/vomiting/diarrhea;&#xD;
&#xD;
               -  Active uncontrolled infection;&#xD;
&#xD;
               -  Symptomatic congestive heart failure;&#xD;
&#xD;
               -  Unstable angina pectoris or cardiac arrhythmia;&#xD;
&#xD;
               -  Psychiatric illness/social situation that would limit compliance with study&#xD;
                  requirements;&#xD;
&#xD;
               -  Focal or generalized seizure within the last 12 months.&#xD;
&#xD;
          4. Any medical condition, which in the opinion of the study investigator, places the&#xD;
             subject at an unacceptably high risk for toxicities;&#xD;
&#xD;
          5. Subject who has received strong inhibitors or inducers of CYP3A, 1A1, 2D6, or 2C19&#xD;
             within 3 days or five half-lives (whichever is shorter) prior to the first dose of&#xD;
             veliparib (applicable to Part 1 only).&#xD;
&#xD;
          6. Subject is pregnant or lactating.&#xD;
&#xD;
          7. Subjects that have previously been treated with a veliparib.&#xD;
&#xD;
          8. For Part 3, subject has ovarian cancer that was previously treated with platinum based&#xD;
             chemotherapy resulting in progression free survival for &lt; 6 months from the completion&#xD;
             of treatment.&#xD;
&#xD;
          9. For Part 3, subject has received 4 or more prior lines of cytotoxic chemotherapy for&#xD;
             systemic disease.&#xD;
&#xD;
         10. Subject who requires parenteral nutrition, tube feeding or has evidence of partial&#xD;
             bowel obstruction or perforation within 28 days prior to study drug administration.&#xD;
&#xD;
         11. The subject has had another active malignancy within the past 3 years except for any&#xD;
             cancer in situ that the Principal Investigator considers to be cured. Questions&#xD;
             regarding the inclusion of individual subject should be directed to the Medical&#xD;
             Monitor.&#xD;
&#xD;
         12. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that&#xD;
             might interfere with gastrointestinal motility, pH or absorption.&#xD;
&#xD;
         13. Receipt of any investigational product within 28 days prior to study drug&#xD;
             administration or 5 half-lives, whichever is longer.&#xD;
&#xD;
         14. Current enrollment in another clinical study.&#xD;
&#xD;
         15. Consideration by the investigator, for any reason, that the subject is an unsuitable&#xD;
             candidate to receive veliparib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Komarnitsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Mittapalli RK, Nuthalapati S, Delke DeBord AE, Xiong H. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation. Pharm Res. 2017 Jun;34(6):1187-1192. doi: 10.1007/s11095-017-2133-3. Epub 2017 Feb 27.</citation>
    <PMID>28243955</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High grade serous ovarian cancer</keyword>
  <keyword>BRCA mutated breast cancer</keyword>
  <keyword>BRCA mutated</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

